Skip to main content

Physician Search

 


Displaying 1 - 2 of 2

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Multiple Cancer Types

This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will
evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
Miscellaneous, Phase I
I/II
Das, Satya
NCT04579757
VICCPHI20125

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Multiple Cancer Types

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety
and efficacy of fruquintinib in combination with tislelizumab in patients with locally
advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety
Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2).

The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D
will be administered to 3 cohorts of patients in the Dose Expansion Phase.

- Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated)

- Cohort B: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-Nave)

- Cohort C: Advanced or Metastatic Endometrial Cancer (EC) (IO-Nave)

- Cohort D: Advanced or Metastatic Colorectal Cancer (mCRC) (IO-Nave)
Miscellaneous, Phase I
I/II
Eng, Cathy
NCT04577963
VICCGIP2223